tlooto
Sign up
MedicinePsychology

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)

I. Litvinenko, Odinak Mm, V. I. Mogil’naya, A. Emelin

2008.10.31Neuroscience and Behavioral Physiology

DOI: 10.1007/s11055-008-9077-3

tlooto Summary

Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations, anxiety, sleep disturbance, and apathy sections.

Abstract

Abstract is not available.

Citation format

LITVINENKO, I., et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with parkinson's disease (an open controlled trial). Neuroscience and Behavioral Physiology, 2008, 38: 937–945.